PRESS CONTENT

FOR IMMEDIATE RELEASE

CONTACT:
Ann Druffner
North America Market Manager Pharmaceuticals
973-628-4103

ISP’s Plasdone® S-630 Copolymer Is Officially Self Affirmed GRAS

WAYNE, N.J. – November 21, 2008 – International Specialty Products (ISP) is pleased to announce that its Plasdone® S-630 Copovidone copolymer has earned self-affirmed Generally Regarded As Safe (GRAS) status. Self-affirmed GRAS signifies that Plasdone® S-630 has been recognized by qualified scientific experts as having been shown to be safe under its intended conditions of use, in this case, as an ingredient in dietary supplements.

Plasdone® S-630 Copovidone is a synthetic, 60:40, linear random copolymer of N-vinyl-2-pyrrolidone and vinyl acetate. The addition of vinyl acetate to the vinylpyrrolidone polymer chain reduces the hydrophilicy and glass transition temperature of the polymer relative to polyvinylpyrrolidone (PVP) homopolymer. These unique properties make Plasdone® S-630 copolymer an excellent adhesive material and make the product well-suited for use in pharmaceutical formulations and dietary supplements as a tablet binder aid in direct compression and dry granulation and as a wet granulation binder of moisture-sensitive actives.

Plasdone® S-630 copolymer conforms to USP/NF and Ph. Eur monograph specifications for Copovidone and the JPE monograph specifications for Copolyvidone.

For more information, send an e-mail to pharmainfo@ispcorp.com, or call 877-389-3083.

****

International Specialty Products Inc. (ISP) is a leading global supplier of specialty chemicals and performance-enhancing products for a wide variety of personal care, pharmaceutical, food, beverage and industrial applications. ISP produces more than 400 specialty chemicals, which it markets and sells worldwide. The company's headquarters is located in Wayne, New Jersey, USA.

This press release may contain “forward-looking statements” within the meaning of the federal securities laws and, as such, concerns matters that are not historical facts. These statements are based on our current expectations and assumptions, which are subject to a number of risks and uncertainties that could cause the actual results to differ materially from those anticipated, projected or implied. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.